FDA’s OCP Maps Out AI, Modeling and Evidence Priorities
FDA’s Office of Clinical Pharmacology (OCP) says regulatory science will have to evolve alongside increasingly complex therapies, with greater use of quantitative modeling, artificial intelligence and translational evidence expected to play a role in future drug development and regulatory decisions. In a just-posted Office of Clinical Pharmacology annual report, OCP outlined its priorities that emphasize model-informed drug development, dose optimization and earlier integration of quantitative evidence into development programs.
The office said the pace and complexity of therapeutic innovation could “outstrip traditional evidentiary frameworks” unless regulatory science advances at a similar pace. OCP said it intends to strengthen the use of exposure-response analyses, dose optimization and assessments of patient variability across development programs and regulatory milestones. A particular focus will be determining when quantitative analyses and mechanistic evidence are sufficiently fit for purpose to reduce uncertainty and support benefit-risk and other regulatory decisions.
Model-informed approaches will remain a central component of that work, although FDA stressed the need for methodological transparency, appropriate validation and results that can be interpreted by multidisciplinary review teams. The office also plans to encourage earlier engagement during drug development so that sponsors' quantitative and translational strategies are designed from the outset to address questions likely to arise during regulatory review.
OCP identified advanced computational methods, AI-enabled tools and novel experimental systems as potentially important ways of making drug development more efficient. But the office signaled that acceptance of those technologies will depend on the strength of the evidence supporting their use. OCP said it intends to evaluate where emerging approaches add value, where they create additional uncertainty, and how they can be implemented into regulatory decision-making. That will require standards for evidentiary sufficiency and a distinction between technologies that show exploratory promise and those that are ready to support regulatory decisions, the office said.
FDA also expects clinical pharmacology to become increasingly important as development shifts toward rare diseases, genetically defined patient subgroups and more complex biological pathways. OCP said it plans to expand work on extrapolation, individualized dosing and methods for assessing pharmacologic evidence in small or heterogeneous populations. Pediatric development, specific populations and therapies proceeding through expedited development programs will also be areas of importance.